Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA, 02115, USA.
Center for Surgery and Public Health, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, 1620 Tremont St, Boston, MA, 02120, USA.
J Gastrointest Surg. 2019 Apr;23(4):720-729. doi: 10.1007/s11605-018-3845-3. Epub 2018 Jun 27.
For gastric neuroendocrine neoplasms (GNEN), the current AJCC lymph node (N) stage classifies patients into N0/N1 disease (with/without locoregional nodal metastases); however, this does not account for the number of involved nodes. The objective of this study was to evaluate the prognostic significance of the number of involved locoregional nodes among resected GNEN.
The National Cancer Database (2004-2014) was queried for GNEN patients who had undergone partial/total gastrectomy with known nodal status. Nearest-neighborhood grouping was used to identify survival clusters by number of metastatic nodes and to use these groupings to construct a new N classification (pN). External validation was performed using the SEER database. Kaplan-Meier analysis and Cox regression models were used to assess the prognostic strength of the pN classification.
One thousand two hundred seventy-five patients met study inclusion criteria. Patients with 1-6 positive nodes (pN1) demonstrated a distinct survival pattern from patients with > 6 positive nodes (pN2) as well as those with no positive nodes (N0) {5-year OS N0: 80% (95% CI 77-83%) vs. 65% (95% CI 61-69%) vs. 43% (95% CI 33-53%), p < 0.001}. On external validation, the pN classification demonstrated strong discriminatory ability for survival {5-year OS N0: 70% (95% CI 65-75%) vs. pN1:53% (95% CI 46-59%) vs. pN2:18% (95% CI 9-29%), p < 0.001}. On multivariable analysis, the pN classification remained an independent predictor of OS.
The number of metastatic lymph nodes is an independent prognostic factor in GNEN. Current AJCC N1 disease contains two groups of patients with distinctive prognoses, hence needs to be subclassified into pN1 (1-6 positive lymph nodes) and pN2 (> 6 positive nodes).
对于胃神经内分泌肿瘤(GNEN),目前的 AJCC 淋巴结(N)分期将患者分为 N0/N1 疾病(有/无局部区域淋巴结转移);然而,这并没有考虑到受累淋巴结的数量。本研究的目的是评估在接受部分/全胃切除的 GNEN 患者中,切除的局部区域淋巴结数量的预后意义。
从 2004 年至 2014 年的国家癌症数据库中查询了接受过已知淋巴结状态的部分/全胃切除术的 GNEN 患者。采用最近邻分组方法,根据转移淋巴结的数量确定生存聚类,并使用这些分组构建新的 N 分类(pN)。使用 SEER 数据库进行外部验证。采用 Kaplan-Meier 分析和 Cox 回归模型评估 pN 分类的预后强度。
1275 名符合研究纳入标准的患者。1-6 个阳性淋巴结(pN1)的患者与 >6 个阳性淋巴结(pN2)和无阳性淋巴结(N0)的患者有明显不同的生存模式{5 年 OS N0:80%(95%CI 77-83%) vs. 65%(95%CI 61-69%) vs. 43%(95%CI 33-53%),p<0.001}。在外部验证中,pN 分类对生存具有很强的判别能力{5 年 OS N0:70%(95%CI 65-75%) vs. pN1:53%(95%CI 46-59%) vs. pN2:18%(95%CI 9-29%),p<0.001}。多变量分析显示,pN 分类仍然是 OS 的独立预测因子。
转移淋巴结的数量是 GNEN 的一个独立预后因素。目前 AJCC 的 N1 疾病包含两组具有不同预后的患者,因此需要进一步分为 pN1(1-6 个阳性淋巴结)和 pN2(>6 个阳性淋巴结)。